SOUTH
SAN FRANCISCO, Calif., Nov. 29,
2022 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ: IDYA), a synthetic lethality-focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics, announced agenda topics and participating
key opinion leaders for its Investor R&D Day. The webcast
event will be hosted by IDEAYA on Monday,
December 12, 2022 at 8:00 am - 9:30
am ET. Registration is available at
https://ir.ideayabio.com/events or
https://lifescievents.com/event/ideaya-rd-day/. The
presentations by IDEAYA management and key opinion leaders will
showcase scientific insights and clinical development opportunities
across IDEAYA's pipeline programs.
Agenda Topics
- The Synthetic Lethality Paradigm
-
- Overview of Current State of Synthetic Lethality Therapy
Opportunity in Oncology
- IDEAYA Vision, Strategy and Pipeline
- Darovasertib Clinical Evaluation in Neoadjuvant Uveal
Melanoma
-
- Clinical Development Plan and Potential Patient Impact
- Mechanistic Advances Support Combination Approaches to Treat
MTAP Deleted Tumors
-
- Dual Synthetic Lethal Strategy for MAT2A Clinical Combination
Therapies
- Selective Essentiality in DNA Damage Repair
-
- Introduction – IDEAYA's DDR Synthetic Lethality Pipeline
- Targeting Replication Stress is an Emerging Synthetic Lethality
Paradigm
- Novel Approach to HRD: IDE161 PARG inhibitor Preclinical
Activity and Clinical Development Plan
- Werner Helicase is a Cornerstone Synthetic Lethality Target for
MSI-High Cancers
- Targeting Pol Theta to Enhance and Maintain Control of HRD
Tumors
Key Opinion Leader Presenters
- Frank McCormick, Ph.D., FRS,
D.Sc (Hon), Professor, Helen Diller Family Comprehensive Cancer
Center and Department of Cellular and Molecular Pharmacology, and
Chair, David A. Wood Distinguished Professorship of Tumor Biology
and Cancer Research, University of California
San Francisco (UCSF)
- Carol Shields, M.D., Chief,
Ocular Oncology Service at Wills Eye Hospital and Professor of
Ophthalmology at Thomas Jefferson
University
- Karlene Cimprich, Ph.D.,
Professor, Chemical and Systems Biology and (by courtesy)
Biochemistry, Member, Stanford Cancer Institute, Stanford University
- Timothy Yap, M.D., Associate
Professor, Department for Investigational Cancer Therapeutics and
Department of Thoracic/Head and Neck Medical Oncology, Medical
Director, Institute for Applied Cancer Science, Associate Director
of Translational Research, Institute for Personalized Cancer
Therapy, M.D. Anderson Cancer Center
- Matthew Garnett, Ph.D., Leader,
Translational Cancer Genomics, Wellcome Sanger Institute
- Benjamin Schwartz, Ph.D., Vice
President, Head of Oncology Synthetic Lethality Research Unit,
GSK
About IDEAYA Biosciences
IDEAYA is a synthetic
lethality focused precision medicine oncology company committed to
the discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with drug discovery to select patient populations most
likely to benefit from its targeted therapies. IDEAYA is applying
its research and drug discovery capabilities to synthetic lethality
– which represents an emerging class of precision medicine
targets.
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to participation in and/or presentation at
certain investor relations events. IDEAYA undertakes no obligation
to update or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the business of IDEAYA in
general, see IDEAYA's Quarterly Report on Form 10-Q filed on
November 8, 2022 and any current and
periodic reports filed with the U.S. Securities and Exchange
Commission.
Investor and Media Contact
IDEAYA Biosciences
Paul Stone
Senior Vice President and Chief Financial Officer
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-agenda-topics-and-key-opinion-leader-presenters-for-investor-rd-day-webcast-on-monday-december-12-2022-301688341.html
SOURCE IDEAYA Biosciences, Inc.